ACTRN12623000526673招募中3 期
A Randomised Controlled Trial of Cannabidiol (CBD) for the treatment of Cannabis Use Disorder (CUD)
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 250
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •1. Aged 18 to 65 years.
- •2. Meeting DSM-5 criteria for moderate or severe Cannabis Use Disorder (more than or equal to 4 out of 11 criteria), with recent frequent cannabis use (more than or equal to 4 days per week in the preceding 4 weeks).
- •3. Willing and able to provide informed consent to study procedures.
- •4. Proficient in English at a conversational level sufficient to participate in counselling intervention (assessed by Study Medical Officer (SMO) at medical assessment).
排除标准
- •1. Prescribed medicinal cannabis products (e.g., CBD, THC) for any indication in the previous 4 weeks.
- •2. Another active (past year) moderate-severe substance use disorder other than tobacco; operationalised on clinical assessment by SMO using DSM5 criteria.
- •3. Active or severe medical (e.g., pain, epilepsy, cardiovascular disease) or psychiatric conditions (e.g., psychosis, severe affective disorder) as identified by the Study Medical Officer; moderate to severe hepatic disease (transaminase elevations more than 3 times, bilirubin more than 2 times upper normal limits).
- •4. Pregnant or lactating women (urine beta-hCG).
- •5. Hypersensitivity to CBD or excipients of Epidyolex.
- •6.Using medications with known drug-drug hepatic CYP-450 interactions with CBD: 3A4, (e.g., carbamazepine, fluvoxamine, methadone), 2C19 (e.g., rifampin); CYP2B6 (e.g., bupropion), CYP2C9 (e.g., warfarin). The potential range of drug-drug interactions are considerable, and the SMO will make an assessment whether the potential for DDI is clinically significant (e.g., as for medications such as warfarin, HIV or anticonvulsant medications), and the SMO can discuss with PI Lintzeris if uncertain.
- •7. Not available for follow-up (e.g., travel, impending imprisonment).
- •8. Court-mandated treatment requiring abstinence from drugs.
- •9. Current active treatment for cannabis use disorder. People in existing treatment counselling and/or medication-based treatment for their cannabis use disorders (e.g., Alcohol and Other Drug services, private health services) are not eligible for the trial at the time of application. To participate, clients would have to choose to cease their existing treatment (counselling, medication) for a 4-week period prior to being formally assessed for the trial.
- •10. Received an investigational medicinal product within the last 4 weeks (or 5 half-lives if using long-acting investigational drugs).
研究者
相似试验
已完成
2 期
A Randomised Control Trial of Cannabinoid Replacement Therapy (SATIVEX - registered trademark) for the Management of Treatment-Resistant Cannabis Dependent Patients in the CommunityCannabis dependenceMental Health - AddictionACTRN12616000103460The University of Sydney142
尚未招募
不适用
An Observation Placebo-controlled Trial with Cannabidiol Added-on Standard Treatment for Thai Patients Suffering from PsoriasisPsoriasis patients with mild to moderate severityPsoriasis, Cannabidiols, CBDTCTR20220208003Faculty of Medicine, Western University70
尚未招募
3 期
A clinical trial to examine the immunomodulatory effect of Triphala in Upper Respiratory Tract Illness in adultsCTRI/2022/08/045079CSIRCIMAP
招募中
3 期
A Prospective Randomized Controlled Clinical Trial of Prophylactic Cranial Irradiation in Metastatic HER-2 positive Breast Cancer.Metastatic HERDŽ positive breast cancer patientsRisk of brain metastasisHER2 positivePCIMetastatic breast cancerTCTR20170612001Ratchadapiseksompotch research fund235
已完成
不适用
A study to assess the effectiveness of Ayurvedic formulation Guduchi Ghan vati in Covid-19 casesCTRI/2020/07/026840Directorate of AYUSH Government of Madhya Pradesh30